Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2014; 20(28): 9229-9236
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9229
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9229
Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers
Tatsuo Kanda, Xia Jiang, Osamu Yokosuka, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Chiba 260-8677, Japan
Author contributions: Kanda T, Jiang X and Yokosuka O solely contributed to this paper.
Supported by Grants for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (to Kanda T)
Correspondence to: Tatsuo Kanda, MD, PhD, Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. kandat-cib@umin.ac.jp
Telephone: +81-43-2262086 Fax: +81-43-2262088
Received: January 17, 2014
Revised: March 7, 2014
Accepted: April 30, 2014
Published online: July 28, 2014
Revised: March 7, 2014
Accepted: April 30, 2014
Published online: July 28, 2014
Core Tip
Core tip: Recent studies have shown that androgen receptor (AR) could play an important role in carcinogenesis and cancer development in hepatocellular carcinoma (HCC) and pancreatic cancer. HCC is a male-dominant cancer. Although pancreatic cancer is not male-dominant, because liver and pancreatic progenitors develop commonly from endoderm cells in the embryonic foregut, AR might play an important role in these cancers.